Resmed delivered a strong quarterly result with record revenue and income for the period

Resmed delivered a strong quarterly result with record revenue and income for the period. Revenue was $397.8million, a 4% increase over the quarter ended March 31, 2013. Net income was $90.0 million an increase of 6% compared to the quarter ended March 31, 2013. In our most recent Buy Hold Sell episode Roger Montgomery, CIO of Montgomery Investment Management, and Don Williams, CIO of Platypus Asset Management, both share their views on Resmed (amongst other healthcare stocks). Both Fund managers rate Resmed as a Buy, citing that the business is coming out of a tough period and growth in the treatment of sleep apnea has plenty of room to go. Earlier this week Livewire contributor Michael Gable also suggested Resmed is now in Buy territory, currently trading at $5.10 Gable sees a long term target of $6. Video here: